What's Actually Changed At FDA: Staffing, Policy, And Predictability

In this segment from the Life Science Leader Live event "FDA Engagement Strategies and Best Practices Amid Agency Changes," Jeremy Levin, Co-Founder and Executive Chairman, Ovid Therapeutics, and Annetta Beauregard, SVP of Science & Regulatory Affairs, BIO, break down the three biggest shifts at the agency — leadership and staffing turnover, new policy tools like the Commissioner's National Priority Voucher program, and predictability challenges that BIO member companies report most often.